ImmunityBio IBRX
$6.02 −$0.55 (-8.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.08 +1.08%
Open$6.41
Prev close$6.57
Day range$6.00 – $6.53
Volume10.64M
Market cap$6.40B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$48.84M+52.3% YoY
Operating profit-$77.99M-40.2% YoY
Net profit-$184.57M-174.3% YoY
Diluted EPS-$0.18-157.1% YoY
Free cash flow-$78.26M-12.3% YoY
Operating cash flow-$75.33M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
Return on assets-196.7%
Current ratio4.27
Liabilities / assets288.0%
Cash & investments$334.33M
Total debt$862.21M
Net cash (debt)-$527.88M
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $48.84M | $51.24M | $44.21M | $113.29M | $38.29M |
| Total Operating Revenue | $48.84M | $51.24M | $44.21M | $113.29M | $38.29M |
| Cost of Revenue | $1.29M | $298,000.00 | $238,000.00 | $753,000.00 | $382,000.00 |
| Gross Profit | $47.55M | $50.94M | $43.97M | $112.54M | $37.90M |
| Operating Expense | $125.54M | $112.64M | $113.76M | $368.56M | $102.59M |
| Selling and Admin Expenses | $54.00M | $51.82M | $45.77M | $150.00M | $38.73M |
| Research & Development | $71.54M | $60.82M | $67.99M | $218.56M | $63.86M |
| Operating Profit | -$77.99M | -$61.70M | -$69.79M | -$256.03M | -$64.68M |
| Net Non-Operating Interest Income (Expense) | -$28.84M | -$28.09M | -$27.73M | -$109.84M | -$28.61M |
| Non-Operating Interest Income | $3.17M | $3.16M | $736,000.00 | $2.69M | -$1.42M |
| Non-Operating Interest Expense | $32.02M | $31.24M | $28.46M | $112.53M | $27.19M |
| Other Income (Expense) | -$77.74M | -$140.60M | -$535.27M | $14.26M | $31.20M |
| Gain on Sale of Security | -$17.33M | -$44.88M | -$292.73M | $59.20M | $33.06M |
| Other Non-Operating Income (Expenses) | -$60.40M | -$95.72M | -$242.54M | -$44.95M | -$1.86M |
| Pretax Profit | -$184.57M | -$230.39M | -$632.79M | -$351.61M | -$62.09M |
| Tax | $0.00 | $0.00 | $9,000.00 | -$135,000.00 | -$135,000.00 |
| Net Profit | -$184.57M | -$230.39M | -$632.80M | -$351.47M | -$61.96M |
| Profit from Continuing Operations | -$184.57M | -$230.39M | -$632.80M | -$351.47M | -$61.96M |
| Minority Interests | -$15,000.00 | -$12,000.00 | -$15,000.00 | -$74,000.00 | -$14,000.00 |
| Net Income to Parent Company | -$184.55M | -$230.38M | -$632.78M | -$351.40M | -$61.94M |
| Net Income to Common Stockholders | -$184.55M | -$230.38M | -$632.78M | -$351.40M | -$61.94M |
| Basic EPS | -$0.17 | -$0.22 | -$0.62 | -$0.38 | -$0.06 |
| Diluted EPS | -$0.18 | -$0.22 | -$0.62 | -$0.38 | -$0.06 |
| Earnings from Equity Interest | – | – | – | $0.00 | – |
| Special Income (Charges) | – | – | – | $0.00 | – |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $609.39M | $628.50M | $646.64M | $501.90M | $501.90M |
| Total Current Assets | $418.79M | $438.98M | $452.95M | $314.88M | $314.88M |
| Cash and Cash Equivalents & Short-Term Investments | $334.33M | $357.37M | $380.88M | $242.82M | $242.82M |
| -Cash and Cash Equivalents | $45.08M | $75.67M | $205.19M | $88.33M | $88.33M |
| -Short Term Investments | $289.25M | $281.70M | $175.69M | $154.48M | $154.48M |
| Receivables | $53.61M | $53.50M | $43.27M | $42.62M | $42.62M |
| -Accounts Receivable | $53.60M | $53.47M | $43.27M | $42.57M | $42.57M |
| -Due from Related Parties Current | $13,000.00 | $27,000.00 | $3,000.00 | $46,000.00 | $46,000.00 |
| Prepaid Assets | $1.56M | $1.35M | $25.23M | $26.40M | $26.40M |
| Inventory | $6,000.00 | $1.94M | $547,000.00 | $910,000.00 | $910,000.00 |
| Other Current Assets | $29.28M | $24.82M | $3.02M | $2.14M | $2.14M |
| Total Non-Current Assets | $190.60M | $189.52M | $193.68M | $187.02M | $187.02M |
| Net PPE | $142.66M | $145.49M | $145.82M | $147.27M | $147.27M |
| -Gross PPE | $142.66M | $145.49M | $261.56M | $259.76M | $259.76M |
| Non-Current Note Receivables | $0.00 | $0.00 | $0.00 | $7.38M | $7.38M |
| Goodwill and Other Intangible Assets | $10.76M | $11.84M | $12.89M | $13.95M | $13.95M |
| Other Non-Current Assets | $37.18M | $32.19M | $34.98M | $18.42M | $18.42M |
| Total Liabilities | $1.75B | $1.67B | $1.52B | $1.00B | $1.00B |
| Total Current Liabilities | $98.09M | $76.73M | $67.95M | $61.75M | $61.75M |
| Payables | $14.87M | $13.55M | $12.12M | $7.38M | $7.38M |
| -Accounts Payable | $13.84M | $12.00M | $11.19M | $6.98M | $6.98M |
| -Due to Related Parties Current | $1.03M | $1.55M | $930,000.00 | $403,000.00 | $403,000.00 |
| Current Accrued Expenses | $75.90M | $55.67M | $34.49M | $23.70M | $23.70M |
| Short-Term Debt and Capital Lease Obligation | $7.31M | $7.51M | $7.63M | $7.54M | $7.54M |
| -Current Capital Lease Obligation | $7.31M | $7.51M | $7.63M | $7.54M | $7.54M |
| Total Non-Current Liabilities | $1.66B | $1.60B | $1.45B | $939.72M | $939.72M |
| Long Term Debt and Capital Lease Obligation | $862.21M | $805.55M | $711.53M | $510.54M | $510.54M |
| -Long Term Debt | $834.94M | $774.35M | $678.39M | $477.09M | $477.09M |
| -Long Term Capital Lease Obligation | $27.27M | $31.20M | $33.15M | $33.45M | $33.45M |
| Derivative Product Liabilities | $367.19M | $376.39M | $331.51M | $104.14M | $104.14M |
| Other Non-Current Liabilities | $427.35M | $415.60M | $404.77M | $325.04M | $325.04M |
| Total Equity | -$1.15B | -$1.05B | -$869.13M | -$499.57M | -$499.57M |
| Stockholders' Equity | -$1.15B | -$1.05B | -$870.01M | -$500.47M | -$500.47M |
| Capital Stock | $106,000.00 | $105,000.00 | $104,000.00 | $101,000.00 | $101,000.00 |
| -Common Stock | $106,000.00 | $105,000.00 | $104,000.00 | $101,000.00 | $101,000.00 |
| Additional Paid-In Capital | $3.60B | $3.52B | $3.46B | $3.20B | $3.20B |
| Retained Earnings | -$4.77B | -$4.59B | -$4.36B | -$3.73B | -$3.73B |
| Gains/Losses Not Affecting Retained Earnings | $26.88M | $27.28M | $27.45M | $28.96M | $28.96M |
| Minority Interests | $853,000.00 | $868,000.00 | $880,000.00 | $895,000.00 | $895,000.00 |
| -Other Intangible Assets | – | $11.84M | $11.98M | $13.04M | $13.04M |
| -Accumulated Depreciation | – | – | -$115.75M | -$112.49M | -$112.49M |
| -Goodwill | – | – | $910,000.00 | $910,000.00 | $910,000.00 |
| Other Current Liabilities | – | – | $2.45M | $3.07M | $3.07M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$75.33M | -$66.49M | -$75.36M | -$304.94M | -$70.38M |
| Net cash flow from continuing operations | -$75.33M | -$66.49M | -$75.36M | -$304.94M | -$70.38M |
| Net Income from Continuing Operations | -$184.57M | -$230.39M | -$632.80M | -$351.47M | -$61.96M |
| Gain/Loss from Continuing Operations | $17.33M | $44.88M | $292.88M | -$53.32M | -$27.18M |
| Depreciation & Depletion & Amortization | $3.89M | $4.41M | $4.38M | $15.53M | $3.87M |
| Other Non-Cash Items | $72.73M | $345.40M | $9.97M | $90.58M | $8.24M |
| Change in Working Capital | $9.21M | -$413,000.00 | -$500,000.00 | -$54.33M | -$14.41M |
| -Change in Receivables | -$126,000.00 | -$10.20M | -$700,000.00 | -$40.21M | -$10.56M |
| -Change in Inventory | -$2.69M | $1.01M | -$4.99M | -$6.33M | -$7.89M |
| -Change in Prepaid Assets | -$4.09M | $1.59M | $559,000.00 | -$4.86M | $3.06M |
| -Change in Payables and Accrued Expense | $18.90M | $8.32M | $7.04M | $2.99M | $2.90M |
| -Change in Other Current Assets | -$396,000.00 | $336,000.00 | -$1.05M | $803,000.00 | -$16,000.00 |
| -Change in Other Current Liabilities | -$1.88M | -$2.06M | -$1.93M | -$7.21M | -$1.84M |
| -Change In Other Working Capital | -$504,000.00 | $595,000.00 | $570,000.00 | $477,000.00 | -$68,000.00 |
| Net cash flow from investing | -$8.04M | -$107.47M | -$31.65M | -$149.80M | $43.57M |
| Net Cash Flow from Continuing Investing Activities | -$8.04M | -$107.47M | -$31.65M | -$149.80M | $43.57M |
| Net PPE Purchase and Sale | -$2.93M | -$3.52M | -$1.78M | -$3.85M | -$903,000.00 |
| Net Intangibles Purchase and Sale | $0.00 | -$23,000.00 | -$11,000.00 | -$406,000.00 | -$372,000.00 |
| Net Investment Purchase and Sale | -$5.12M | -$103.93M | -$29.86M | -$145.55M | $44.85M |
| Financing Cash Flow | $53.03M | $44.44M | $223.93M | $400.24M | $54.89M |
| Net Cash Flow from Continuing Financing Activities | $53.03M | $44.44M | $223.93M | $400.24M | $54.89M |
| Net Issuance Payments Of Debt | $3.05M | -$12,000.00 | $48,000.00 | $2.86M | $2.87M |
| Net Common Stock Issuance | $28.40M | $45.05M | $102.23M | $400.56M | $53.74M |
| Proceeds from Stock Option Exercised | $21.59M | $347,000.00 | $47.52M | -$2.05M | -$590,000.00 |
| Net Other Financing Charges | -$3,000.00 | -$940,000.00 | $74.13M | -$1.13M | – |
| Ending Cash Balance | $46.36M | $76.95M | $206.47M | $89.43M | $89.43M |
| Net Change in Cash | -$30.34M | -$129.52M | $116.92M | -$54.50M | $28.09M |
| Beginning Cash Balance | $76.95M | $206.47M | $89.43M | $143.91M | $61.34M |
| Effect of Exchange Rate Changes | -$244,000.00 | -$3,000.00 | $122,000.00 | $15,000.00 | $5,000.00 |
| Free Cash Flow | -$78.26M | -$70.03M | -$77.15M | -$309.19M | -$71.65M |
No comments yet — be the first to weigh in on IBRX.
Sign in to join the discussion.